Citi downgrades BioMarin Pharmaceutical (Nasdaq: BMRN) from Buy to Hold. Price target lowered from $22 to $17.

Citi ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE